Table 1 Baseline characteristics
Baseline characteristics | Mesalazine arm | Placebo arm |
|---|---|---|
Number enrolled | 22 | 22 |
Age (months) | 19 (14 to 32) | 19 (15 to 29) |
Sex: Male | 10 (45) | 11 (50) |
Female | 12 (55) | 11 (50) |
Household income category (USD/day)a | $2 to $4 | $2 to $4 |
Number of people living in the house | 5 (4 to 7) | 5 (4 to 5) |
Access to improved drinking water sourceb | 100% | 100% |
Access to improved toilet facility | 50% | 41% |
MUAC (cm) | 12.9 (11.2 to 14.4) | 12.7 (11.2 to 13.8) |
Height-for-age z-score | -3.13 (-3.83 to -2.71) | -3.73 (-4.60 to -2.81) |
Nutritional edema | 15 (68) | 17 (77) |
Current breastfeedingc | 11 (50) | 5 (23) |
Symptoms: Fever | 10 (45) | 8 (36) |
Cough | 9 (41) | 6 (27) |
Diarrhea | 5 (23) | 5 (23) |
Biochemistry: Creatinine (umol/L) | 18 (17 to 23) | 19 (17 to 22) |
AST (IU/L) | 37 (27 to 52) | 40 (32 to 49) |
ALT (IU/L) | 24 (12 to 31) | 17 (15 to 30) |
CRP (mg/L) | 6.0 (1.3 to 10.8) | 6.8 (1.6 to 42.2) |
Hematology: Hemoglobin (g/dL) | 10.3 (7.9 to11.2) | 9.6 (8.2 to 10.6) |
WBC count (x 109/L) | 12.0 (9.9 to 15.1) | 11.8 (9.3 to 13.6) |
Platelet count (x 109/L) | 555 (423 to 666) | 536 (282 to 692) |
ESR (mm/hour) | 32 (24 to 38) | 33 (28 to 44) |